Introduction: Pemetrexed is a first line drug for brain metastases from lung cancer, either as monotherapy or combined with other drugs. The frequent occurrence of initial and acquired resistance to ...

2017; Scherpereel et al., 2018). Combination treatment with pemetrexed (PMX, also known as Alimta and LY231514) and cisplatin has been the first-line chemotherapy regimen for more than a decade ...

The leading Triple Negative Breast Cancer Companies such as Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Non-small cell lung cancer comprises the majority of all lung cancers—which is the leading cause of cancer death across the world. Patients older than age 70 make up a large portion of all patients ...

Data from the Phase 3 PALOMA-3 study showed non-inferiority to intravenous administration meeting both co-primary pharmacokinetic (PK) endpoints, as well as a five-fold reduction in infusion-related ...

在非小细胞肺癌中，KRAS基因突变的比例不是特别高，其中KRAS基因G12C突变在白种人突变的概率是10%，在亚裔患者的突变概率是3%。经过数十年的研究，针对KRAS基因G12C目前已经有了靶向药，Sotorasib（中文翻译为：索托拉西布）是一种口服靶向药。在相应的三期临床试验中，相比化疗药多西他赛，索托拉西布显著延长了患者的中位 ...

Placebo and Pembrolizumab in those with PD-L1 expression >=50% or LY3537982 and Pembrolizumab, Pemetrexed, Platinum vs. Placebo and Pembrolizumab, Pemetrexed, Platinum regardless of PD-L1 expression.

The combination of brain radiotherapy and chemoimmunotherapy “resulted in promising intracranial and systemic anti-tumor activity, with a manageable safety profile,” researchers wrote.